Kazia Therapeutics Ltd · NASDAQ:KZIA

Kazia Therapeutics — Investor Presentation (January 2022)

41 slides from Kazia Therapeutics's investor presentation, Jan 19, 2022

  1. Slide 1: Kazia Corporate Presentation (ASX Release)

    ASX RELEASE 19 January 2022 KAZIA CORPORATE PRESENTATION Sydney, 19 January 2022 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide its latest corporate presentation, which will be used for investor meetings over the coming mont

  2. Slide 2: For more information, please visit www.kaziatherapeutics.com

    For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx. This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.

  3. Slide 3: A Diversified Oncology Drug Development Company

    A Diversified Oncology Drug Development Company Corporate Introduction January 2022 ASX: KZA | NASDAQ: KZIA | Twitter: @KaziaTx

  4. Slide 4: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All state

  5. Slide 5: Company Overview

    Company Overview An oncology drug-development company Lead Program in Phase III for Diversified Clinical-Stage Strong Corporate Glioblastoma Pipeline Fundamentals Paxalisib EVT801 • Potential first-in-class therapy for • Potential best-in-class therapy for • Listed on ASX (KZA) and on the most commo

  6. Slide 6: Corporate History

    Corporate History Kazia has shown remarkable growth in five years October 2016 May 2018 November 2019 January 2021 April 2021 Paxalisib (then Phase II clinical First interim Paxalisib begins EVT801 licensed in known as GDC- study of paxalisib efficacy date from recruitment to GBM from Evotec SE 0084

  7. Slide 7: 2021 in Review

    2021 in Review A Year of Delivering Milestones 3 $15M 5 179% Clinical studies Major cross-border Total shareholder initiated across a licensing deals in Revenue in FY2021 return (TSR) variety of oncology FY2021 (Jul 20 to Jun 21) indications Phase 3 3 >200 Phase 1 Advanced Paxalisib New paxalisib tr

  8. Slide 8: Pipeline

    Pipeline Two world-class assets in clinical trials by end CY2021 licensed from: Paxalisib (formerly GDC-0084) Small molecule, highly potent, brain-penetrant inhibitor of PI3K / mTOR PRECLIN. PHASE 1 PHASE 2 PHASE 3 MARKET Glioblastoma Most common primary brain cancer DIPG Highly aggressive childhood

  9. Slide 9: Operating Model

    Operating Model In-licensing advanced assets drives earlier value realization A Proven Strategy Jun 2010 – licensed niraparib from Merck Mar 2017 – Zejula® (niraparib) approved by FDA License under- Develop value Partner for Dec 2018 – Tesaro acquired by GSK valued assets through late-stage from lar

  10. Slide 10: Leadership

    Leadership 160+ years of international drug development experience Board Management Team Iain Ross Dr James Garner Chairman Chief Executive Officer & Executive Director Executive and Board roles in pharma Physician / MBA; Extensive drug and small biotech development experience Bryce Carmine Dr John

  11. Slide 11: Financial Metrics

    as at 31 DEC 21 Financial Metrics Value-driving news flow for investors Share Price (US$) 16.00 Market Capitalisation US$ 125M 14.00 Listing KZIA ASX (primary) KZA Kazia Therapeutics 12.00 NASDAQ (ADSs @ 1:10 ratio) KZIA ↓ 3% Shares on Issue 130M 10.00 NBI Nasdaq Biotech Index Balance Sheet US$ ↓ 1%

  12. Slide 12: CY2022 Milestones and Newsflow

    CY2022 Milestones and Newsflow Multiple catalysts across two clinical programs Open GBM AGILE paxalisib arm to recruitment in EU and China 1H CY2022 Commence recruitment to paxalisib phase II GBM study at Weill Cornell 1H CY2022 Initial interim data from paxalisib + trastuzumab phase II metastatic H

  13. Slide 13: Investment Rationale

    Investment Rationale A compelling corporate story High-Quality Valuable Efficient, Well- Rapid Path to Late-Stage Commercial Funded Business Value Realisation Pipeline Opportunities • Pipeline assets • Glioblastoma alone is • Board & management • Paxalisib in phase III invented by world- a ~US$ 1.5B

  14. Slide 14: Paxalisib

    Paxalisib Glioblastoma Phase III DIPG Phase II PCNSL Phase II Brain Metastases Phase II 11

  15. Slide 15: Treatment of brain cancer has improved little in recent decades

    Treatment of brain cancer has improved little in recent decades, unlike other cancers Lung 1990s 2000s 2010s Cancer Brain Cancer 1990s 2000s 2010s (glioblastoma) 12

  16. Slide 16: Paxalisib was designed to overcome key challenges in brain cancer treatment

    Paxalisib was designed specifically to overcome key challenges in the treatment of brain cancer Crosses Blood-Brain Barrier Oral Presentation Most anti-cancer drugs are not brain penetrant 15mg capsule, taken once daily; no significant food effect Targets PI3K / mTOR Pathway Strong IP Protection Com

  17. Slide 17: Glioblastoma is the most common and aggressive primary brain cancer

    Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung No clear Any age, No clear but most improvement in cause common in prognosis for Breast or strong risk factors 60s 20 years 14 million cancer cases per annum Colon 3-4 months 12-15 Five-year survival Prostate

  18. Slide 18: Temozolomide is the only FDA-approved first-line GBM treatment

    Temozolomide is only FDA-approved first-line treatment for GBM; it is ineffective in ~65% of cases Standard of Care Debulking surgery Radiotherapy + Temozolomide (‘Stupp where possible temozolomide maintenance therapy Regimen’) 6 weeks 4w 6 x 28-day cycles Methylated MGMT Status ~35% of patients res

  19. Slide 19: The PI3K / Akt / mTOR pathway is a critical signalling mechanism

    The PI3K / Akt / mTOR pathway is a critical signalling mechanism for many tumor types Growth factor receptors Paxalisib Among Most Potent PI3K Inhibitors (e.g. EGFR, HER2) IC50 (nM) Idealisib (Gilead) p110a p110b p110g p110d mTORC PI3K 1/2 Alpelisib (Novartis) Paxalisib 2 46 10 3 70 Idelalisib 820 5

  20. Slide 20: Paxalisib is unique among PI3K inhibitors in crossing the blood-brain barrier

    The PI3K inhibitor class is well-established, but paxalisib is unique in its ability to cross the blood-brain barrier Zydelig Aliqopa Copiktra Piqray Ukoniq paxalisib (idelalisib) (copanlisib) (duvelisib) (alpelisib) (umbralasib) FDA Approved FDA Approved FDA Approved FDA Approved FDA Approved In pi

  21. Slide 21: Paxalisib shows single-agent activity in preclinical glioblastoma models

    Paxalisib shows convincing single-agent activity in preclinical models of glioblastoma Illustrative Dose-Dependent Activity in U87 Model General Findings Tumor Volume (mm3) Widespread activity in a range of PDX Vehicle models; appears unaffected by MGMT 0.03 mg/kg promotor status 0.45 mg/kg 2.2 mg/k

  22. Slide 22: Phase II mono-therapy study in newly-diagnosed GBM shows efficacy signal

    FINAL DATA Phase II study of paxalisib mono-therapy in newly-diagnosed GBM provides robust signal of clinical efficacy Progression-Free Survival (PFS) Overall Survival (OS) (n=30) (n=30) Paxalisib 8.4 months Paxalisib 15.7 months Temozolomide Temozolomide (Historical) 5.3 months (Historical) 12.7 mo

  23. Slide 23: Safety profile in phase 2 GBM study is generally mild to moderate

    INTERIM DATA Safety Profile in the phase 2 clinical study in GBM patients is generally mild to moderate, reversible, and manageable Number of Patients at 60mg (n=24) Experiencing AEs ‘Possibly’ or ‘Likely’ Related to Paxalisib (affecting ≥2 patients) Term Gr 1 Gr 2 Gr 3 Gr 4 Total (%) Rash 4 6 7 17

  24. Slide 24: Eight unique clinical studies are ongoing

    Eight unique clinical studies are ongoing across a variety of solid tumours with CNS involvement Registration Indication Phase N Status Sponsor Primary Brain Cancer Glioblastoma Up to 200 on NCT03970447 II / III Recruiting (GBM AGILE) paxalisib Glioblastoma NCT05183204 II 33-60 Recruiting (combinati

  25. Slide 25: GBM AGILE international pivotal study is underway

    GBM AGILE international pivotal study is underway Sponsored by GCAR with support of GBM key opinion leaders Key Points Regorafenib • A ‘platform study’, run Bayer independently of individual Paxalisib 3 companies, designed to expedite Kazia Therapeutics Economies of scale the approval of new drugs f

  26. Slide 26: Paxalisib validated by licensing deal, with scope for indication expansion

    Paxalisib validated by commercial licensing deal, with significant scope for indication expansion Opportunities ‘Blue Sky’ Other Cancers with PI3K Partnership with Simcere Pharmaceutical for Greater Dysregulation China signed in March 2021 (e.g. breast, lung) Simcere will develop and commercialise p

  27. Slide 27: Adoption rate expected to be very high due to scarcity of treatment options

    Adoption rate for the commercial product is expected to be very high, due to scarcity of existing treatment options Newly-Diagnosed Unmethylated Recurrent Extension of Overall Survival (months) Extension of Overall Survival (months) Optimal 7.0 mos. Optimal 4.8 mos. Minimum 2.6 mos. Minimum 2.1 mos.

  28. Slide 28: Payer interviews support willingness-to-pay up to US$20K in US

    Payer interviews support willingness-to-pay up to US$ 20K in US and up to ~$10K in EU5 United States European Union Likelihood of Coverage for Paxalisib Likelihood of Coverage for Paxalisib Very 7 Very 7 Favourable Favourable 6 6 5 5 4 4 3 3 2 2 1 1 Not At All Not At All Favourable Favourable 0 0 $8

  29. Slide 29: Key Points

    Key Points • Well-validated mechanism (PI3K inhibition) but unique differentiating feature (brain penetration) • Positive phase II data in GBM, supported by very strong preclinical package and positive phase I data • Fully-funded international registration study underway with full support of FDA and

  30. Slide 30: EVT801 Solid Tumors Phase I

    EVT801 Solid Tumors Phase I 27

  31. Slide 31: Targeting angiogenesis is a well-established approach in cancer treatment

    Targeting angiogenesis is a well-established approach in the treatment of cancer Product Company Target Indications Annual Sales (US$)* • Colorectal cancer VEGF-A • Lung cancer $7 billion • Breast cancer VEGFR • Hepatocellular carcinoma PDGFR • Renal call carcinoma $1 billion RAF kinases • Thyroid c

  32. Slide 32: Angiogenesis inhibitors are limited by several key challenges

    Despite their proven efficacy, angiogenesis inhibitors are limited by several key challenges 1 Angiogenesis inhibitors work by reducing Tumor Hypoxia the formation of new blood vessels around the tumor, starving it of vital Sustained tumor hypoxia activates adaptive mechanisms, Limited nutrients nee

  33. Slide 33: EVT801 is a selective VEGFR3 inhibitor

    EVT801 is a selective VEGFR3 inhibitor, primarily inhibiting lymphangiogenesis (formation of new lymphatic vessels) Highly selective for VEGFR3 Oral Presentation Expected to minimise off-target toxicities Administered by mouth once or twice daily Inhibits lymphangiogenesis Strong IP Protection Compo

  34. Slide 34: EVT801 selectively inhibits VEGFR3

    EVT801 selectively inhibits VEGFR3 Avastin Lucentis (bevacizumab) (ranibizumab) VEGF-B VEGF-A VEGF-D VEGF-E VEGF-C Sutent EVT801 (sunitinib) VEGFR1 VEGFR2 VEGFR3 Nexavar (sorafenib) Inlyta Cell Survival Signal Modulation Angiogenesis (axitinib) Votrient Lymphangio- Vasculogenesis genesis (panzopanib

  35. Slide 35: EVT801 is expected to have three primary mechanisms of action

    EVT801 is expected to have three primary mechanisms of action Tumor Killing 1 Direct effect on VEGFR3-expressing tumor cells (typically from endothelial origin, e.g. sarcoma) 3 3 Increase in Anti-Tumor Immune Activity 2 Increased infiltration of effector T-cells, and reduction in immunosuppressive 1

  36. Slide 36: Preclinical data confirms activity of EVT801 (1/2)

    Preclinical data confirms activity of EVT801 (1/2) Dramatic single-agent activity in DEN-induced HCC model Tumor Growth Metastasis Experimental Methods Total Tumor Volume Number of Tumors in the Liver • Syngeneic mouse model • Hepatocellular carcinoma chemically 85% reduction 50% reduction induced w

  37. Slide 37: Preclinical data confirms activity of EVT801 (2/2)

    Preclinical data confirms activity of EVT801 (2/2) Synergistic activity in combination with anti-CTLA4 mAb Tumor Volume (mm3) Experimental Methods 500 • Orthotopic mouse model Vehicle • 4T1 tumor cells inoculated in BALB/c EVT801 mice (mammary fat pad) 400 anti-CTLA4 • Treatment with EVT801 on D7-D2

  38. Slide 38: Focus in angiokinase inhibitor class has shifted to immuno-oncology

    Focus in the ‘angiokinase inhibitor’ class has shifted from anti-angiogenic use to immuno-oncology use Select VEGFR Inhibitors – FDA Approvals – 2012-2021 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 Renal Renal Cancer Cancer (MonoTx) with Thyroid Renal Liver Endomet- Renal Cancer Cancer Cancer

  39. Slide 39: Kazia's strategy for EVT801 explores both areas of opportunity

    PRELIMINARY Kazia’s strategy for EVT801 aims to explore both areas of opportunity for the drug Explore EVT801 as Phase II Study Pivotal Study an anti-angiogenic therapy, likely in Monotherapy Monotherapy tumours that ONGOING express high One or more solid One or more solid VEGFR3 tumours tumours Pha

  40. Slide 40: Key Points

    Key Points • Well-understood mechanism (anti-angiogenesis) but unique differentiating feature (VEGFR3 selectivity) • Very strong preclinical data package, with evidence of activity in multiple tumors and favourable toxicology • High potential for combination use with immuno- oncology therapies • Ada

  41. Slide 41: www.kaziatherapeutics.com

    www.kaziatherapeutics.com info@kaziatherapeutics.com

Kazia Therapeutics — Investor Presentation (January 2022) on 6ix